SCHEMBL2932047

SCHEMBL2932047

O=Cc1ccccc1C(=O)N1CCN(c2ccccc2)CC1.c1ccc2c(c1)CO2

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
TSHR P16473 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
USP2 O75604 3/20 0.58
MAPT P10636 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
HPGD P15428 1/20 0.53
LMNA P02545 3/20 0.52
HTT P42858 1/20 0.52
HSD17B10 Q99714 2/20 0.48
TP53 P04637 2/20 0.48
HSP90AA1 P07900 1/20 0.47
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GFER P55789 2/20 0.46
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932523 0.79 CYP2C9 (0.57) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL20140579 0.78 ALDH1A1 (0.64) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL10724385 0.76 ALDH1A1 (1.00) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL1662914 0.75 GAA (0.59) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL22551122 0.72 HTT (0.55) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL18046217 0.71 ALDH1A1 (0.61) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL29609156 0.71 ALDH1A1 (0.61) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL18046220 0.71 ALDH1A1 (0.61) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL9565911 0.70 ALDH1A1 (0.81) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL15347660 0.69 ALDH1A1 (1.00) ALDH1A1TSHRMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656361-B1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-02 EP claimed
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
EP-1656361-B1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 ALDH1A1 2527/4885TSHR 220/4885MEN1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.